NCT06982313View on ClinicalTrials.gov

Long-term Follow-up of the TAM-01 Study

Not yet recruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2026

Study Completion Date

February 28, 2035

Conditions
Breast Cancer Invasive
Interventions
DRUG

Tamoxifen (Nolvadex)

5 mg per day for 3 years during TAM-01 phase III trial

DRUG

Tamoxifen (Nolvadex) placebo

Tamoxifen (Nolvadex) placebo per day for 3 years during TAM-01 phase III trial.

Trial Locations (1)

Unknown

E. O. Ospedali Galliera, Genoa

All Listed Sponsors
lead

Ente Ospedaliero Ospedali Galliera

OTHER